| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $5,036,464 ) |
| | 2026 | 2026 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI136064 | Direct-from-specimen identification of pathogens common in endocarditis | 000 | 7 | NIH | 6/19/2026 | $986,903 |
| | 2026 | 2026 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI186712 | An automated culture-free system for the identification of bloodstream infections direct from blood | 000 | 3 | NIH | 6/30/2026 | $1,019,702 |
| | 2026 | 2026 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI157322 | Direct-from-specimen characterization of bloodstream infections | 000 | 4 | NIH | 8/6/2026 | $1,000,000 |
| | 2026 | 2026 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | SB1AI183963 | Commercialization Readiness Pilot (CRP) program support for: Ultra-sensitive, direct-from-blood, molecular detection of Borrelia infections. | 000 | 3 | NIH | 5/27/2026 | $1,000,000 |
| | 2026 | 2026 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI197309 | Automated system for the direct from blood characterization of bloodstream infections | 000 | 1 | NIH | 7/16/2026 | $1,029,859 |
| | 2026 | 2025 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI174578 | Diagnostic tool for assessment and tracking of microbial load in bloodstream infections | 000 | 3 | NIH | 3/2/2026 | $0 |
| | 2026 | 2025 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | SB1AI172440 | Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditis | 000 | 3 | NIH | 3/2/2026 | $0 |
| | 2026 | 2024 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | SB1AI172427 | Commercialization Readiness Pilot (CRP) program support for: An Integrated Device for identification of bloodstream infections directly from blood | 000 | 3 | NIH | 6/9/2026 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $5,074,337 ) |
| | 2025 | 2025 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI136064 | Direct-from-specimen identification of pathogens common in endocarditis | 000 | 6 | NIH | 12/12/2024 | $1,049,999 |
| | 2025 | 2025 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI174578 | Diagnostic tool for assessment and tracking of microbial load in bloodstream infections | 000 | 3 | NIH | 6/13/2025 | $996,497 |
| | 2025 | 2025 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | SB1AI172440 | Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditis | 000 | 3 | NIH | 6/11/2025 | $1,000,000 |
| | 2025 | 2025 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI186712 | An automated culture-free system for the identification of bloodstream infections direct from blood | 000 | 2 | NIH | 7/2/2025 | $1,027,841 |
| | 2025 | 2025 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | SB1AI183963 | Commercialization Readiness Pilot (CRP) program support for: Ultra-sensitive, direct-from-blood, molecular detection of Borrelia infections. | 000 | 2 | NIH | 4/30/2025 | $1,000,000 |
| | 2025 | 2024 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI172441 | Direct detection and identification of antimicrobial resistance genes in bloodstream infections | 000 | 3 | NIH | 7/14/2025 | $0 |
| | 2025 | 2024 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI165300 | Direct from blood identification of bloodstream infections in newborns | 000 | 3 | NIH | 7/23/2025 | $0 |
| | 2025 | 2023 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI157322 | Direct-from-specimen characterization of bloodstream infections | 000 | 3 | NIH | 6/10/2025 | $0 |
| | 2025 | 2023 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI124726 | An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood | 000 | 6 | NIH | 6/10/2025 | $0 |
| | 2025 | 2022 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI152628 | Development of an automated IVD for the ultra-sensitive, direct, molecular detection of Borrelia for early Lyme Disease | 000 | 3 | NIH | 1/8/2025 | $0 |
| | 2025 | 2022 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI109913 | A Culture-Free Platform for Rapid Fungal Pathogen Identification | 000 | 6 | NIH | 10/29/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $7,979,298 ) |
| | 2024 | 2024 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | SB1AI183963 | Commercialization Readiness Pilot (CRP) program support for: Ultra-sensitive, direct-from-blood, molecular detection of Borrelia infections. | 000 | 1 | NIH | 4/2/2024 | $1,000,000 |
| | 2024 | 2024 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI174578 | Diagnostic tool for assessment and tracking of microbial load in bloodstream infections | 000 | 2 | NIH | 5/31/2024 | $985,142 |
| | 2024 | 2024 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI136064 | Direct-from-specimen identification of pathogens common in endocarditis | 001 | 5 | NIH | 1/19/2024 | $1,001,029 |
| | 2024 | 2024 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI172441 | Direct detection and identification of antimicrobial resistance genes in bloodstream infections | 000 | 3 | NIH | 7/24/2024 | $1,000,000 |
| | 2024 | 2024 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | SB1AI172440 | Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditis | 000 | 2 | NIH | 5/23/2024 | $997,234 |
| | 2024 | 2024 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI186712 | An automated culture-free system for the identification of bloodstream infections direct from blood | 000 | 1 | NIH | 7/8/2024 | $1,000,000 |
| | 2024 | 2024 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | SB1AI172427 | Commercialization Readiness Pilot (CRP) program support for: An Integrated Device for identification of bloodstream infections directly from blood | 000 | 3 | NIH | 3/1/2024 | $1,000,000 |
| | 2024 | 2024 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI165300 | Direct from blood identification of bloodstream infections in newborns | 001 | 3 | NIH | 7/26/2024 | $995,893 |
| | 2024 | 2023 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI165300 | Direct from blood identification of bloodstream infections in newborns | 000 | 2 | NIH | 7/26/2024 | $0 |
| | 2024 | 2021 | HELIXBIND, INC. | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI136064 | Direct-from-specimen identification of pathogens common in endocarditis | 000 | 4 | NIH | 1/9/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $7,041,282 ) |
| | 2023 | 2023 | HELIXBIND INC | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI172441 | Direct detection and identification of antimicrobial resistance genes in bloodstream infections | 000 | 2 | NIH | 8/3/2023 | $1,000,000 |
| | 2023 | 2023 | HELIXBIND INC | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI165300 | Direct from blood identification of bloodstream infections in newborns | 000 | 2 | NIH | 7/7/2023 | $991,282 |
| | 2023 | 2023 | HELIXBIND INC | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | SB1AI172427 | Commercialization Readiness Pilot (CRP) program support for: An Integrated Device for identification of bloodstream infections directly from blood | 000 | 2 | NIH | 2/24/2023 | $1,000,000 |
| | 2023 | 2023 | HELIXBIND INC | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI174578 | Diagnostic tool for assessment and tracking of microbial load in bloodstream infections | 000 | 1 | NIH | 6/23/2023 | $1,050,000 |
| | 2023 | 2023 | HELIXBIND INC | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI157322 | Massively Multiplexed dsDNA Invasion Arrays | 000 | 3 | NIH | 3/13/2023 | $1,000,000 |
| | 2023 | 2023 | HELIXBIND INC | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | SB1AI172440 | Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditis | 000 | 1 | NIH | 6/20/2023 | $1,000,000 |
| | 2023 | 2023 | HELIXBIND INC | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R44AI124726 | An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood | 000 | 6 | NIH | 3/28/2023 | $1,000,000 |
|
| Issue Date FY: 2022 ( Subtotal = $7,025,221 ) |
| | 2022 | 2022 | HELIXBIND INC. | 181 CEDAR HILL ST STE 1 | MARLBOROUGH | MA | 01752-3057 | MIDDLESEX | USA | R44AI109913 | A Culture-Free Platform for Rapid Fungal Pathogen Identification | 000 | 6 | NIH | 3/29/2022 | $1,000,000 |
| | 2022 | 2022 | HELIXBIND INC. | 181 CEDAR HILL ST STE 1 | MARLBOROUGH | MA | 01752-3057 | MIDDLESEX | USA | R44AI124726 | An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood | 000 | 5 | NIH | 3/29/2022 | $1,000,000 |
| | 2022 | 2022 | HELIXBIND INC. | 181 CEDAR HILL ST STE 1 | MARLBOROUGH | MA | 01752-3057 | MIDDLESEX | USA | R44AI152628 | Development of an automated IVD for the ultra-sensitive, direct, molecular detection of Borrelia for early Lyme Disease | 000 | 3 | NIH | 5/16/2022 | $980,611 |
| | 2022 | 2022 | HELIXBIND INC. | 181 CEDAR HILL ST STE 1 | MARLBOROUGH | MA | 01752-3057 | MIDDLESEX | USA | R44AI165300 | Direct from blood identification of bloodstream infections in newborns | 000 | 1 | NIH | 8/1/2022 | $994,610 |
| | 2022 | 2022 | HELIXBIND INC. | 181 CEDAR HILL ST STE 1 | MARLBOROUGH | MA | 01752-3057 | MIDDLESEX | USA | R44AI172441 | Direct detection and identification of antimicrobial resistance genes in bloodstream infections | 000 | 1 | NIH | 8/9/2022 | $1,050,000 |
| | 2022 | 2022 | HELIXBIND INC. | 181 CEDAR HILL ST STE 1 | MARLBOROUGH | MA | 01752-3057 | MIDDLESEX | USA | SB1AI172427 | Commercialization Readiness Pilot (CRP) program support for: An Integrated Device for identification of bloodstream infections directly from blood | 000 | 1 | NIH | 3/3/2022 | $1,000,000 |
| | 2022 | 2022 | HELIXBIND INC. | 181 CEDAR HILL ST STE 1 | MARLBOROUGH | MA | 01752-3057 | MIDDLESEX | USA | R44AI157322 | Massively Multiplexed dsDNA Invasion Arrays | 000 | 2 | NIH | 4/1/2022 | $1,000,000 |
| | 2022 | 2018 | HELIXBIND INC | 1300 MASSACHUSETTS AVE | BOXBOROUGH | MA | 01719-2200 | MIDDLESEX | USA | R43AI136064 | Culture-free identification of pathogens common in endocarditis directly from patient specimens | 000 | 1 | NIH | 9/26/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $4,992,384 ) (Continued on the next page) |
|
| Loading… |
|
